Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Diabetic retinopathy is one of the worst complications of diabetes and it is treated by invasive method. We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segmen...

Full description

Bibliographic Details
Main Authors: Umesh D. Laddha, Sanjay J. Kshirsagar
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:Heliyon
Subjects:
Nanoparticle
PPAR-gamma
VEGF
Diabetic retinopathy
Box-Behnken statistical design
PLGA
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402031433X

Similar Items

Similar Items